Noesis Capital Mangement Corp Buys 4,425 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Noesis Capital Mangement Corp boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 116,113 shares of the biopharmaceutical company’s stock after acquiring an additional 4,425 shares during the period. Gilead Sciences accounts for about 1.9% of Noesis Capital Mangement Corp’s holdings, making the stock its 21st biggest position. Noesis Capital Mangement Corp’s holdings in Gilead Sciences were worth $9,735,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. CarsonAllaria Wealth Management Ltd. raised its stake in Gilead Sciences by 198.3% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 238 shares during the period. nVerses Capital LLC purchased a new position in shares of Gilead Sciences in the third quarter worth about $25,000. Valued Wealth Advisors LLC raised its position in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares during the period. Cedar Wealth Management LLC lifted its stake in shares of Gilead Sciences by 51.6% during the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 160 shares in the last quarter. Finally, Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences in the 2nd quarter worth approximately $33,000. 83.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on GILD. The Goldman Sachs Group lifted their price target on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Leerink Partnrs raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Truist Financial upped their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a report on Friday, November 8th. Barclays boosted their target price on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 7th. Finally, Oppenheimer raised their price target on Gilead Sciences from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Twelve investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $95.41.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. This trade represents a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now owns 8,920 shares in the company, valued at $815,198.80. This trade represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 63,735 shares of company stock valued at $5,589,030 over the last quarter. 0.29% of the stock is owned by company insiders.

Gilead Sciences Stock Up 1.2 %

Shares of NASDAQ GILD opened at $92.41 on Thursday. The company has a market cap of $115.17 billion, a price-to-earnings ratio of 1,026.78, a PEG ratio of 2.81 and a beta of 0.17. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The firm’s fifty day moving average is $87.91 and its 200 day moving average is $77.42. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. During the same period in the prior year, the firm posted $2.29 earnings per share. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. On average, equities research analysts expect that Gilead Sciences, Inc. will post 4.37 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.33%. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.